The Weight-Loss Gold Rush: Legal and Regulatory Implications

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.

• Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
• How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
• What needs to be done for GLP-1s to be covered
• Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
• Advice for investors and financiers who are considering entering the weight-loss medication market